The article provides an overview of analyst ratings for Intellia Therapeutics over the past 3 months. While the majority of analysts are somewhat bullish, the average 12-month price target has decreased by 6.84% from the previous average. This suggests that there may be some uncertainty in the market, leading to a neutral short-term impact on the stock price.